Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
Dana-Farber Cancer Institute
Celgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Pfizer
Dartmouth-Hitchcock Medical Center
European Myeloma Network B.V.
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Massachusetts General Hospital
Dana-Farber Cancer Institute
BioLineRx, Ltd.
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
University of Washington
Memorial Sloan Kettering Cancer Center